Erfindergemeinschaft UroPep GbR v. Eli Lilly and Company et al, No. 2:15-cv-01202 (E.D. Tex. Mar. 13, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court are (1) Defendant Eli Lilly & Company’s Motion and Memorandum of Law in Support of Its Motion in Limine, Dkt. No. 198, and (2) Plaintiff UroPep’s Motions In Limine, Dkt. No. 207. Following briefing, 1 the Court heard argument on the motions on February 21, 2017. Beginning with the motions in limine of plaintiff Erfindergemeinschaft UroPep GbR (“UroPep”), and then addressing those of defendant Eli Lilly & Co. (“Lilly ”), the dispositions of the individual motions in limine are as follows: 1.